NASDAQ:LPTX Leap Therapeutics (LPTX) Stock Price, News & Analysis $0.51 +0.06 (+13.00%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Leap Therapeutics Stock (NASDAQ:LPTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Leap Therapeutics alerts:Sign Up Key Stats Today's Range$0.46▼$0.5250-Day Range$0.24▼$0.4552-Week Range$0.22▼$4.79Volume1.56 million shsAverage Volume1.70 million shsMarket Capitalization$21.05 millionP/E RatioN/ADividend YieldN/APrice Target$3.38Consensus RatingHold Company Overview Leap Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for the treatment of cancer. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Leap’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion. DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies. In addition to DKN-01, Leap is advancing preclinical programs that target novel pathways involved in cancer cell signaling and immune regulation, with the aim of identifying complementary assets for future clinical development. Founded in 2016 and headquartered in Irvine, California, Leap Therapeutics completed its initial public offering in 2019 and trades on the NASDAQ under the ticker LPTX. The company conducts clinical trials in the United States and collaborates with academic and industry partners to accelerate its development programs. Michael Stoll, M.D., serves as President and Chief Executive Officer, overseeing a team of experienced professionals in oncology drug discovery and development.AI Generated. May Contain Errors. Read More Leap Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreLPTX MarketRank™: Leap Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 582nd out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingLeap Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialLeap Therapeutics has a consensus price target of $3.38, representing about 590.2% upside from its current price of $0.49.Amount of Analyst CoverageLeap Therapeutics has received no research coverage in the past 90 days.Read more about Leap Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Leap Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Leap Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Leap Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLeap Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Leap Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.25% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Leap Therapeutics has recently decreased by 13.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLeap Therapeutics does not currently pay a dividend.Dividend GrowthLeap Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.25% of the float of Leap Therapeutics has been sold short.Short Interest Ratio / Days to CoverLeap Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Leap Therapeutics has recently decreased by 13.41%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment0.95 News SentimentLeap Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Leap Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for LPTX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Leap Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Leap Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.46% of the stock of Leap Therapeutics is held by institutions.Read more about Leap Therapeutics' insider trading history. Receive LPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LPTX Stock News HeadlinesLeap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025September 25, 2025 | prnewswire.comLeap Therapeutics Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised to benefit from this massive shift inside my Bull Run Millionaire Blueprint.October 1 at 2:00 AM | Crypto 101 Media (Ad)Leap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deLeap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comLeap Therapeutics, Inc. (LPTX) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comLeap Therapeutics Initiates Process To Explore Strategic OptionsJune 24, 2025 | nasdaq.comLeap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesJune 23, 2025 | prnewswire.comSee More Headlines LPTX Stock Analysis - Frequently Asked Questions How have LPTX shares performed this year? Leap Therapeutics' stock was trading at $2.88 at the start of the year. Since then, LPTX shares have decreased by 83.0% and is now trading at $0.4890. How were Leap Therapeutics' earnings last quarter? Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.11. When did Leap Therapeutics' stock split? Shares of Leap Therapeutics reverse split on Wednesday, June 21st 2023.The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Leap Therapeutics? Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Leap Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Vaxart (VXRT) and OPKO Health (OPK). Company Calendar Last Earnings8/14/2025Today10/01/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LPTX CIK1509745 Webwww.leaptx.com Phone(617) 714-0360FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Leap Therapeutics$3.38 High Price Target$5.50 Low Price Target$1.25 Potential Upside/Downside+643.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-237.65% Return on Assets-155.38% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book0.50Miscellaneous Outstanding Shares41,440,000Free Float38,332,000Market Cap$18.81 million OptionableOptionable Beta-0.21 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:LPTX) was last updated on 10/1/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondMost “hot AI stocks” will vanish — but Weiss Ratings’ system, ranked #1 for accuracy, just flagged 10 AI stock...Weiss Ratings | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredNIL is on Fire. This Nasdaq Saw It ComingTikTok made influencers the new storefront. NIL made college athletes the new marketers. Now, one Nasdaq br...i2i Marketing Group, LLC | SponsoredTrump is Fast-Tracking These Three CompaniesThe Trump administration is planning to invest DIRECTLY in a small sector of the stock market… And they just r...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.